Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.<sup>1</sup> and Zhang et al.<sup>2</sup> in Cell Reports Medicine and Cell Reports, respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels.
Authors
- Amirhossein Sahebkar (ORCID: https://orcid.org/0000-0002-8656-1444)
- Maciej Banach (ORCID: https://orcid.org/0000-0001-6690-6874)
Institutions
- Johns Hopkins University (US)
- Mashhad University of Medical Sciences (IR)
- Medical University of Lodz (PL)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.xcrm.2024.101726
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- National Science Foundation
- Iran National Science Foundation